Atherosclerosis regression and TP receptor inhibition

Effect of S18886 on plaque size and composition - A magnetic resonance imaging study

Juan F. Viles-Gonzalez, Valentin Fuster, Roberto Corti, Carolina Valdiviezo, Randolph Hutter, Stefano Corda, Sunil X. Anand, Juan J. Badimon

Research output: Contribution to journalArticle

Abstract

Aims: Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogenesis. A growing body of evidence suggests that inhibition of the thromboxane A2 (TxA2 or TP) receptor may improve endothelial function and reduce the inflammatory component of atherosclerosis in addition to its demonstrated antiplatelet activity. Consequently, we sought to assess the effect of a novel TP receptor antagonist S18886, on atherosclerotic lesion progression and composition by serial non-invasive magnetic resonance imaging (MRI). Methods and results: S18886 was compared with control in an experimental model of established aortic atherosclerosis in New Zealand White rabbits (n = 10). The animals underwent MRI of the abdominal aorta at the time of randomization and at the end of treatment. Subsequently, animals were euthanized and specimens were stained for histopathology and immunohistochemistry with anti-α-actin antibodies for vascular smooth muscle cells (VSMC), anti-RAM-11 for macrophages, anti-caspase-3 for apoptotic cells, anti-MMP-1 for metalloproteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial dysfunction. MRI analysis revealed a significant reduction in total vessel area (TVA) and vessel wall area (VWA) in the S18886 group (P <0.05). Immunostaining analysis showed a significant decrease in RAM-11, caspase-3, MMP-1, ET-1 and an increase in α-actin in the treated group (P <0.05 vs. control). Conclusion: Inhibition of the TP receptor by S18886 causes a regression of advanced atherosclerotic plaques. In addition, the reduction in the markers for macrophages, apoptotic cells, metalloproteinases, and endothelin-1 and the increase in VSMC, suggests that S18886 may not only halt the progression of atherosclerosis, but also transform lesions towards a more stable phenotype. The possibility of combining antithrombotic and antiatherosclerotic activity by means of the administration of TP inhibitors deserves further investigation in a clinical setting.

Original languageEnglish (US)
Pages (from-to)1557-1561
Number of pages5
JournalEuropean Heart Journal
Volume26
Issue number15
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

terutroban
Thromboxane Receptors
Atherosclerosis
Magnetic Resonance Imaging
Endothelin-1
Vascular Smooth Muscle
Caspase 3
Smooth Muscle Myocytes
Actins
Macrophages
Matrix Metalloproteinase 1
Thromboxane A2
Abdominal Aorta
Metalloproteases
Atherosclerotic Plaques
Random Allocation
Matrix Metalloproteinases
Anti-Idiotypic Antibodies
Theoretical Models
Blood Platelets

Keywords

  • Antiplatelets
  • Atherosclerosis
  • Magnetic resonance imaging
  • MRI
  • Platelets
  • Thromboxane A2
  • Thromboxane receptor
  • TP receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Viles-Gonzalez, J. F., Fuster, V., Corti, R., Valdiviezo, C., Hutter, R., Corda, S., ... Badimon, J. J. (2005). Atherosclerosis regression and TP receptor inhibition: Effect of S18886 on plaque size and composition - A magnetic resonance imaging study. European Heart Journal, 26(15), 1557-1561. https://doi.org/10.1093/eurheartj/ehi175

Atherosclerosis regression and TP receptor inhibition : Effect of S18886 on plaque size and composition - A magnetic resonance imaging study. / Viles-Gonzalez, Juan F.; Fuster, Valentin; Corti, Roberto; Valdiviezo, Carolina; Hutter, Randolph; Corda, Stefano; Anand, Sunil X.; Badimon, Juan J.

In: European Heart Journal, Vol. 26, No. 15, 08.2005, p. 1557-1561.

Research output: Contribution to journalArticle

Viles-Gonzalez, JF, Fuster, V, Corti, R, Valdiviezo, C, Hutter, R, Corda, S, Anand, SX & Badimon, JJ 2005, 'Atherosclerosis regression and TP receptor inhibition: Effect of S18886 on plaque size and composition - A magnetic resonance imaging study', European Heart Journal, vol. 26, no. 15, pp. 1557-1561. https://doi.org/10.1093/eurheartj/ehi175
Viles-Gonzalez, Juan F. ; Fuster, Valentin ; Corti, Roberto ; Valdiviezo, Carolina ; Hutter, Randolph ; Corda, Stefano ; Anand, Sunil X. ; Badimon, Juan J. / Atherosclerosis regression and TP receptor inhibition : Effect of S18886 on plaque size and composition - A magnetic resonance imaging study. In: European Heart Journal. 2005 ; Vol. 26, No. 15. pp. 1557-1561.
@article{2941e9dda5f1408e890c7d87d15495c8,
title = "Atherosclerosis regression and TP receptor inhibition: Effect of S18886 on plaque size and composition - A magnetic resonance imaging study",
abstract = "Aims: Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogenesis. A growing body of evidence suggests that inhibition of the thromboxane A2 (TxA2 or TP) receptor may improve endothelial function and reduce the inflammatory component of atherosclerosis in addition to its demonstrated antiplatelet activity. Consequently, we sought to assess the effect of a novel TP receptor antagonist S18886, on atherosclerotic lesion progression and composition by serial non-invasive magnetic resonance imaging (MRI). Methods and results: S18886 was compared with control in an experimental model of established aortic atherosclerosis in New Zealand White rabbits (n = 10). The animals underwent MRI of the abdominal aorta at the time of randomization and at the end of treatment. Subsequently, animals were euthanized and specimens were stained for histopathology and immunohistochemistry with anti-α-actin antibodies for vascular smooth muscle cells (VSMC), anti-RAM-11 for macrophages, anti-caspase-3 for apoptotic cells, anti-MMP-1 for metalloproteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial dysfunction. MRI analysis revealed a significant reduction in total vessel area (TVA) and vessel wall area (VWA) in the S18886 group (P <0.05). Immunostaining analysis showed a significant decrease in RAM-11, caspase-3, MMP-1, ET-1 and an increase in α-actin in the treated group (P <0.05 vs. control). Conclusion: Inhibition of the TP receptor by S18886 causes a regression of advanced atherosclerotic plaques. In addition, the reduction in the markers for macrophages, apoptotic cells, metalloproteinases, and endothelin-1 and the increase in VSMC, suggests that S18886 may not only halt the progression of atherosclerosis, but also transform lesions towards a more stable phenotype. The possibility of combining antithrombotic and antiatherosclerotic activity by means of the administration of TP inhibitors deserves further investigation in a clinical setting.",
keywords = "Antiplatelets, Atherosclerosis, Magnetic resonance imaging, MRI, Platelets, Thromboxane A2, Thromboxane receptor, TP receptor",
author = "Viles-Gonzalez, {Juan F.} and Valentin Fuster and Roberto Corti and Carolina Valdiviezo and Randolph Hutter and Stefano Corda and Anand, {Sunil X.} and Badimon, {Juan J.}",
year = "2005",
month = "8",
doi = "10.1093/eurheartj/ehi175",
language = "English (US)",
volume = "26",
pages = "1557--1561",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Atherosclerosis regression and TP receptor inhibition

T2 - Effect of S18886 on plaque size and composition - A magnetic resonance imaging study

AU - Viles-Gonzalez, Juan F.

AU - Fuster, Valentin

AU - Corti, Roberto

AU - Valdiviezo, Carolina

AU - Hutter, Randolph

AU - Corda, Stefano

AU - Anand, Sunil X.

AU - Badimon, Juan J.

PY - 2005/8

Y1 - 2005/8

N2 - Aims: Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogenesis. A growing body of evidence suggests that inhibition of the thromboxane A2 (TxA2 or TP) receptor may improve endothelial function and reduce the inflammatory component of atherosclerosis in addition to its demonstrated antiplatelet activity. Consequently, we sought to assess the effect of a novel TP receptor antagonist S18886, on atherosclerotic lesion progression and composition by serial non-invasive magnetic resonance imaging (MRI). Methods and results: S18886 was compared with control in an experimental model of established aortic atherosclerosis in New Zealand White rabbits (n = 10). The animals underwent MRI of the abdominal aorta at the time of randomization and at the end of treatment. Subsequently, animals were euthanized and specimens were stained for histopathology and immunohistochemistry with anti-α-actin antibodies for vascular smooth muscle cells (VSMC), anti-RAM-11 for macrophages, anti-caspase-3 for apoptotic cells, anti-MMP-1 for metalloproteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial dysfunction. MRI analysis revealed a significant reduction in total vessel area (TVA) and vessel wall area (VWA) in the S18886 group (P <0.05). Immunostaining analysis showed a significant decrease in RAM-11, caspase-3, MMP-1, ET-1 and an increase in α-actin in the treated group (P <0.05 vs. control). Conclusion: Inhibition of the TP receptor by S18886 causes a regression of advanced atherosclerotic plaques. In addition, the reduction in the markers for macrophages, apoptotic cells, metalloproteinases, and endothelin-1 and the increase in VSMC, suggests that S18886 may not only halt the progression of atherosclerosis, but also transform lesions towards a more stable phenotype. The possibility of combining antithrombotic and antiatherosclerotic activity by means of the administration of TP inhibitors deserves further investigation in a clinical setting.

AB - Aims: Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogenesis. A growing body of evidence suggests that inhibition of the thromboxane A2 (TxA2 or TP) receptor may improve endothelial function and reduce the inflammatory component of atherosclerosis in addition to its demonstrated antiplatelet activity. Consequently, we sought to assess the effect of a novel TP receptor antagonist S18886, on atherosclerotic lesion progression and composition by serial non-invasive magnetic resonance imaging (MRI). Methods and results: S18886 was compared with control in an experimental model of established aortic atherosclerosis in New Zealand White rabbits (n = 10). The animals underwent MRI of the abdominal aorta at the time of randomization and at the end of treatment. Subsequently, animals were euthanized and specimens were stained for histopathology and immunohistochemistry with anti-α-actin antibodies for vascular smooth muscle cells (VSMC), anti-RAM-11 for macrophages, anti-caspase-3 for apoptotic cells, anti-MMP-1 for metalloproteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial dysfunction. MRI analysis revealed a significant reduction in total vessel area (TVA) and vessel wall area (VWA) in the S18886 group (P <0.05). Immunostaining analysis showed a significant decrease in RAM-11, caspase-3, MMP-1, ET-1 and an increase in α-actin in the treated group (P <0.05 vs. control). Conclusion: Inhibition of the TP receptor by S18886 causes a regression of advanced atherosclerotic plaques. In addition, the reduction in the markers for macrophages, apoptotic cells, metalloproteinases, and endothelin-1 and the increase in VSMC, suggests that S18886 may not only halt the progression of atherosclerosis, but also transform lesions towards a more stable phenotype. The possibility of combining antithrombotic and antiatherosclerotic activity by means of the administration of TP inhibitors deserves further investigation in a clinical setting.

KW - Antiplatelets

KW - Atherosclerosis

KW - Magnetic resonance imaging

KW - MRI

KW - Platelets

KW - Thromboxane A2

KW - Thromboxane receptor

KW - TP receptor

UR - http://www.scopus.com/inward/record.url?scp=25444465119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444465119&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehi175

DO - 10.1093/eurheartj/ehi175

M3 - Article

VL - 26

SP - 1557

EP - 1561

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 15

ER -